Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

Valued at a market cap of $164.8 billion, Pfizer Inc. (PFE) discovers, manufactures, distributes, and markets medicines and ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective oestrogen ...